Acethylcholine esterase inhibitors as a means of reducing the effects of increased stress or its prevention - in iatrogenic Cushing's syndrome and others, i.a. HPA-mediated undesirable effects in high-dose, long-lasting gluto

摘要

Use of acetylcholinesterase inhibitors as a medication, characterized by new, previously unknown effects for the reduction and prevention of stress-related symptoms / disorders of iatrogenic and / or bio-psycho-social aetiology: 1. as a medication with new, previously unknown effects in glucocorticoid therapy, 1.1. characterized by the reduction and prevention of the following undesirable effects in the initial phase of glucocorticoid therapy 1.1.1. seizure-related tachycardia, 1.1.2. Arrhythmia, 1.1.3. pectanginal seizures, 1.1.4. elevated blood pressure, 1.1.5. Lifting and dizzy spells, 1.1.6. eerie feelings in the head and chest, 1.1.7. Heat and sweat attacks, 1.1.8. Polypnea, 1.1.9. Visual disturbances that may be associated with dilated pupils, 1.1.10. occasionally photopsies, 1.1.11. sounding noises, 1.1.12. Constipation, 1.1.13. Sleep Disorders, 1.1.14. Tremor, 1.1.15. inner unrest; 1.2. characterized by the reduction and prevention of iatrogenic Cushing syndrome with 1.2.1. Moon Face, Buffalo Neck, 1.2.2. Hypertension, 1.2.3. Diabetes mellitus, 1.2.4. Obesity strain, 1.2.5. sec. Amenorrhoea, 1.2.6. Growth disorders in childhood; 1.3. characterized by the amelioration of the following diseases resulting from glucocorticoid therapy: 1.3.1. Osteoporosis, 1.3.2. Glaucoma; 2. as a medication with new, previously unknown effects, characterized by the reduction / elimination of stress-related symptoms in psychiatric, psychosomatic and / or psycho-social disorders: 2.1. Anxiety disorders and phobias 2.1.1. Panic Disorders 2.1.2. Fear of heights 2.1.3. Claustrophobia 2.1.4. Test anxiety 2.1.5. social anxiety 2.2. depressive disorders, 2.3. Burnout, 2.4. Stress disorders, 2.5. Adjustment disorders, 2.6. sympathicotonic sleep disorders, 2.7. ADHD; 3. as a medication with new, previously unknown effects, characterized by the significant reduction / elimination of central sympathetic excitation with corresponding symptoms in: 3.1. Borderline hypertension, 3.2. severe, long or chronic diseases; 4. A method for achieving the effect according to claims 1 to 3, characterized in that the intake of an acetylcholinesterase inhibitor takes place half an hour before meals and at bedtime and additional income when needed are possible.